BioXcel Therapeutics (BTAI) announced that, following the successful raise of $14 million gross proceeds in an equity financing that closed on ...

Shares of BioXcel Therapeutics stock opened at $3.37 on Monday. The stock has a market capitalization of $10.45 million, a price-to-earnings ratio of -0.10 and a beta of 0.89. BioXcel Therapeutics ...

In this article, we are going to take a look at where BioXcel Therapeutics, Inc. (NASDAQ:BTAI) stands against the other stocks. Micro- and small-cap companies dominated the stock market last week ...

BioXcel Therapeutics announced that the FDA has concluded its inspection of a site in the Phase 3 TRANQUILITY II trial for BXCL501. BioXcel Therapeutics' stock soared following the FDA's ...

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company currently trading at $2.16, has announced several updates including regulatory developments, trial progress, and corporate ...

NEW HAVEN, Conn. - BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company leveraging artificial intelligence in drug development, announced that the U.S. Food and Drug ...

BioXcel Therapeutics, Inc. announced it has raised $14 million in equity financing, providing the company with approximately $35 million in cash to support its pivotal Phase 3 SERENITY At-Home ...

The market expects BioXcel Therapeutics, Inc. (BTAI) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely ...

We recently compiled a list of the 10 Micro-, Small-Cap Firms Were Last Week's Top Performers. In this article, we are going to take a look at where BioXcel Therapeutics, Inc. (NASDAQ:BTAI) stands ...

BioXcel Therapeutics announces 33% enrollment in SERENITY At-Home trial evaluating BXCL501 for agitation treatment, with data expected mid-2025. BioXcel Therapeutics announced that it has achieved ...